FDA Approves Another Indication for Merck & Co.'s Recarbrio
05 June 2020 - 8:03AM
Dow Jones News
By Josh Beckerman
Merck & Co.'s Recarbrio received U.S. Food and Drug
Administration approval to treat hospital-acquired bacterial
pneumonia and ventilator-associated bacterial pneumonia.
Recarbrio, a combination of imipenem-cilastatin and relebactam,
was previously approved to treat certain patients with complicated
urinary tract infections and complicated intra-abdominal
infections.
The FDA said the application was granted a Qualified Infectious
Disease Program designation.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 04, 2020 17:48 ET (21:48 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.